The assessment of Empagliflozin Effects in diabetic patients with coronary artery disease: The EMPA-CARD Randomized Clinical Trial

Zanjan University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新: 2020年6月15日

试验速览

暂无简介。

•Age between 40-75 year-old
•HbA1c between 6.5 to 9
•Diabetes mellitus type 2
•Under fix continues anti-diabetic treatment for at least 3 month
•BMI less than 40
•Fixed Diet and physical activity
•Resting heart rate between 60 to 100 b/min
•Use of Aspirin 80 mg/Daily for at least 3 month prior to the beginning of study
•Glomerular filtration rate (GFR)>45
•Documented known Coronary Artery Disease

•Heart Failure (NYHA class 3-4), Ejection Fraction <40%
•History of allergic reaction to SGLT2 inhibitors Drugs
•History of SGLT2 inhibitor Drugs usage
•Gastrointestinal malabsorbtion disease
•History of CABG, ACS, TIA,CVA or PCI during past 3 month
•History or presence of malignancy
•Anemia (Hb<10 g/dl)
•History of heart or lung transplant
•Major psychiatric disorders
•History of DKA
•Elevated liver enzymes >3 times upper normal limit
•Use of drugs prolonging QT interval
•Presence of Arrhythmia
•Electrolyte disorders
•Patients with Pace Maker
•Use of anti-coagulant or anti-platelet drugs for at least 3 months prior to the sampling
•Consumption of alcohol, Anti inflammatory drugs (except Aspirin) or Anti oxidant supplement
•Platelet count <100000/µl
•History of infection during 1 one month before sampling

发起方